Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

at the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Complete if Known

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete ii Known			
Application Number	10/722,858		
Filing Date	November 26, 2003		
First Named Inventor	Hector F. DeLuca		
Art Unit	1621		
Examiner Name			
Attamas Dankat Mumbar	1256 00020		

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SM		^{US-} 5,936,133	08-10-1999	DeLuca et al	
(1/1/		^{US-} 5,581,006	12-03-1996	DeLuca et al	
917		^{US-} 5,086,191	02-04-1992	DeLuca et al	
180		US-			
· V		US-			
		US-		,	
		US-			
	l	US-			
	_	US-			
		US-			
		US-	1		

		FORE	IGN PATENT DOCU	MENTS	•	
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Г
		Country Code ³ Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
						-
	ļ					┢
	<u> </u>					┢
	 					

Examiner Signature	Slin belan	Date Considered 4/2/12/01/9

EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw time through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the region of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is statched.

This collection of information is required by 37 CER 1.97 and 1.98. The information is required to obtain or retain a benefit by the mubils which is to file food by the

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE vork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
Subsului	8 101 101111 1443/F1C	•		Application Number	10/722,858	
INFO	DRMATIO	N DIS	CLOSURE	Filing Date	November 26, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Hector F. DeLuca	
				Art Unit	1621	
	(Use as many si	neets as ne	ecessary)	Examiner Name		
Sheet	2	of	3	Attorney Docket Number	1256-00929	

		NON PATENT LITERATURE DOCUMENTS		l
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
M		Abstract 122:81736; SICINSKI ET AL; Synthesis and Biological Activity of 2-Hydroxy and 2-Alkoxy Analogs of 1Alpha,25-Dihydroxy-19-Norvitamin D3; Journal of Medicinal Chemistry; 1994, 37(22), 3730-8		
U		Abstract 115:92747, BAKER ET At: Design and Synthesis of 6Alpha-Substituted 2Beta Alpha-Dihydroxy-1Beta-Phosphoryloxycyclohexanes, Potent Imibitors of Inceitel Menophosphatase; Journal of the Chemical Society, Chemical Communications; 1991, (5), 298-300	als	0
JAN,		Abstract 127:359017; KOZIKOWSKI ET AL; Synthesis of 1D-3-Deoxy- and -2,3-Dideoxyphosphatidylinositol; Tetrahedron; 1997, 53(44), 14903-14914		
And		Abstract 114:7016; CAMBIE ET AL; A Stereocontrolled Synthesis of Proto-Quercitol; Australian Journal of Chemistry; 1990, 43(9), 1597-602		
X		Abstract 115:92747; BAKER ET AL; Design and Synthesis of 6Alpha-Substituted-2Beta-Phosphoryloxycyclohexanes, Potent Inhibitors of Inositol Monophosphatase; Journal of the Chemical Society, Chemical Communications; 1991, (5), 298-300		1
U XI		Abstract 130:263914; IWASE ET AL; Bioscience, Biotechnology, and Biochemistry; 1998, 62(12), 2396-2407		
A		Abstract 96:163074; YOSHIKAWA ET AL; Heterocycles, 1982, 17 (Spec. Issue), 209-14		
M		SICINSKI ET AL; New 1Alpha,25-Dihydroxy-19-Norvitamin D3 Compounds of High Biological Activity: Synthesis and Biological Evaluation of 2-Hydroxymethyl, 2-Methyl, and 2-Methylene Analogues; Journal of Medicinal Chemistry; 1998, (41), 4662-4674		
(h)		POSNER ET AL; Stereocontrolled Synthesis of a Trihydroxylated A Ring as an Immediate Precursor to 1Alpha,2Alpha,25-Trihydroxyvitamin D3; Journal of Organic Chemistry; 1991, (56), 4339-4341		
		PERLMAN ET AL; 1Alpha,25-Dihydroxy-19-Nor-Vitamin D3, A Novel Vitamin D-Related Compound with Potential Therapeutic Activity; Tetrahedron Letters, 1990, (31), 13, 1823-1824		

	1					_
έx Θ		/ant/a	flam	Date	Cany 21 2014	
Si	gnature	Jun P V	uan.	Considered	apm 21 noy	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is statched.

1 Applicant's unique citation of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Conflightfaility is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

Application Number 10/722,858 ATION DISCLOSURE Filing Date November 26, 2003	
ATION DISCESSORE	
ENT BY APPLICANT First Named Inventor Hector F. DeLuca	
Art Unit 1621	
Examiner Name	
3 of 3 Attorney Docket Number 1256-00929	
Examiner Name Attorney Docket Number 1050, 00000	

·		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AN		PERLMAN ET AL; Novel Synthesis of 19-Nor-Vitamin D Compounds; Tetrahedron Letters, 1991, (32), 52, 7663-7666	
V			
		·	

Examiner Signature	Sant Villar	Date Considered	april 2014

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application—Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.